Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves' disease

dc.creatorSantos, RB
dc.creatorRomaldini, JH
dc.creatorWard, LS
dc.date2004
dc.dateJUL
dc.date2014-11-16T15:51:54Z
dc.date2015-11-26T17:25:42Z
dc.date2014-11-16T15:51:54Z
dc.date2015-11-26T17:25:42Z
dc.date.accessioned2018-03-29T00:12:55Z
dc.date.available2018-03-29T00:12:55Z
dc.identifierThyroid. Mary Ann Liebert Inc Publ, v. 14, n. 7, n. 525, n. 530, 2004.
dc.identifier1050-7256
dc.identifierWOS:000223071500008
dc.identifier10.1089/1050725041517093
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/70569
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/70569
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/70569
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1284378
dc.descriptionIn order to assess the effect of propylthiouracil (PTU) or methimazole (MMI) pretreatment on patient outcome after radioiodine therapy, we examined 100 patients with Graves' disease 3, 6, 9, and 12 months after administration of a 10-mCi standard single dose of I-131. They were assigned to one of three groups: no drug (ND) treatment (30 cases); MMI (45 cases); and PTU (25 cases). Antithyroid drugs (ATD) were withdrawn 15 days before radioiodine administration. The groups were similar concerning age, gender, ATD pretreatment duration, goiter size, and initial serum triiodothyronine (T-3), thyroxine (T4), free thyroxine (FT4), antithyroid autoantibody levels, 24-hour radioiodine uptake and I-131 dose administered per gram of thyroid tissue. ND and MMI groups presented a similar rate of cure of 73.3% and 77.8% respectively (p = NS). In contrast, the PTU group showed a rate of cure of only 32% (p < 0.05). Logistic regression analysis indicated that PTU administration (p = 0.003) and thyroid size (p = 0.02) were the variables related to radioiodine therapy failure. Our data demonstrate that the chance of I-131 treatment failure is higher in individuals using PTU than in patients using MMI or not using any ATD before radioiodine (odds ratio [OR] = 5.84; 95% confidence interval [CI] = 1.82-18.76) suggesting that PTU should be avoided in the treatment of patients with Graves' disease.
dc.descriptiono TEXTO COMPLETO DESTE ARTIGO, ESTARÁ DISPONÍVEL À PARTIR DE AGOSTO DE 2015.
dc.description14
dc.description7
dc.description525
dc.description530
dc.languageen
dc.publisherMary Ann Liebert Inc Publ
dc.publisherLarchmont
dc.publisherEUA
dc.relationThyroid
dc.relationThyroid
dc.rightsembargo
dc.sourceWeb of Science
dc.subjectRadioactive Iodine Therapy
dc.subjectAntithyroid Drugs
dc.subjectCase Selection
dc.subjectI-131 Therapy
dc.subjectCure Rates
dc.subjectMethimazole
dc.subjectPretreatment
dc.subjectEfficacy
dc.subjectCarbimazole
dc.subjectMethylmercaptoimidazole
dc.titlePropylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves' disease
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución